Videos

Sara Assaf, MD, shares insights on selecting biologic therapies for severe asthma, including biomarkers, patient factors, and managing nonresponders effectively.

The FDA's approval of GLP-1 for obstructive sleep apnea enhances treatment options, emphasizing pharmacists' vital role in patient care and management.

Panelists discuss how the MK-3475A-D77 trial demonstrated subcutaneous pembrolizumab’s pharmacokinetic comparability and equivalent efficacy to IV formulation in patients with metastatic non–small cell lung cancer receiving combination chemotherapy, with administration requiring approximately 2 minutes for 5 mL volume and showing comparable safety profiles.

Panelists discuss how the IMscin001 trial established subcutaneous atezolizumab’s pharmacokinetic equivalency to IV formulation with comparable efficacy and 4.5% injection site reactions, while highlighting operational implementation challenges, including building multiple indication-specific order sets and standardizing varying administration times across different subcutaneous products.

Panelists discuss how subcutaneous nivolumab demonstrates reassuring safety profiles with minimal grade 3 and 4 adverse events comparable to those of IV formulation, produces pharmacokinetically equivalent or slightly higher drug exposure, and shows numerically similar or higher objective response rates, making patient education about injection site reactions the primary consideration.

Panelists discuss how the CheckMate67T trial demonstrated pharmacokinetic noninferiority and comparable efficacy and safety between subcutaneous and IV nivolumab, with subcutaneous administration requiring only 3 to 5 minutes vs 30-minute infusions and showing mild, transient injection site reactions in approximately 8% of patients.

Samantha Picking, PharmD, outlines how Walgreens enhances immunization access through digital innovation, patient engagement, and ongoing pharmacist training.

Balazs Halmos, MD, discusses how the COPERNICUS trial aims to build on previous amivantamab studies.

In the ARANOTE trial, darolutamide combined with ADT significantly delayed disease progression and maintained quality of life for patients with metastatic hormone-sensitive prostate cancer, supporting its use as a chemotherapy-free option.

Nicoletta Colombo, MD, PhD, discusses why metronomic chemotherapy dosing and careful regimen design may have driven the success of the KEYNOTE-B96 trial.

Datopotamab deruxtecan-dlnk improved duration of response by roughly 5 months compared with chemotherapy in first-line mTNBC.

At ESMO 2025, Felix Guerrero-Ramos, MD, discussed SunRISe-1 data showing durable responses and low toxicity with TAR-200, the importance of training in device management, and how future biomarker research may refine patient selection and combination strategies.

Andrea Necchi, MD, shared SunRISe-4 primary results demonstrating higher pathologic response and relapse-free survival rates with TAR-200 plus sacituzumab compared with checkpoint inhibitor monotherapy, with no new safety signals observed.

Stephen Freedland, MD, highlighted data showing significant overall survival benefits in the EMBARK trial and discussed the continued role of monotherapy in preserving quality of life for select patients.

Thor Halfdanarson, MD, discussed early results showing favorable response rates and manageable safety with ^212Pb-VMT-α-NET, along with the role of PET imaging in optimizing patient selection for future trials.

Felix Guerrero-Ramos, MD, outlines molecular and pharmacologic findings from SunRISe-1, including the high prevalence of TP53 alterations and the extended drug exposure achieved with the TAR-200 intravesical delivery system.

Oncologist Thor Halfdanarson reviews dose-finding data for the targeted α radioligand therapy [^212Pb]VMT- α-NET, highlighting manageable toxicity, stable renal function, and plans for phase 2 evaluation.

Pranav Garimella, MBBS, MPH, emphasizes that pharmacists are essential partners in managing chronic kidney disease, ensuring safe medication use, adherence, and coordinated care alongside physicians.

Ron Lanton outlines enforcement uncertainty and downstream effects on biosimilars, specialty drugs, and pharmacy supply chains under most favored nation pricing proposals.

Panelists discuss how evaluating quality of life in patients on CDK4/6 inhibitors requires asking open-ended questions beyond just adverse effects to assess social functioning, work capacity, and emotional well-being (with quality of life data showing these agents maintain rather than significantly improve outcomes), and how multidisciplinary care can be optimized through nurse navigators for additional patient touchpoints, coordination with subspecialty colleagues like pulmonology and cardio-oncology for rare toxicities, and utilizing learners and standardized workflows to manage the high patient volume despite limited pharmacist resources.

Panelists discuss how treatment sequencing in early-stage breast cancer requires a stepwise approach, adding one therapy at a time (typically radiation, then hormonal therapy, then CDK4/6 inhibitors, with special considerations for BRCA-positive patients receiving olaparib first), while in metastatic settings the sequencing is more straightforward with first-line CDK4/6 inhibitors plus endocrine therapy, and how patient adherence can be optimized through shared decision-making, detailed toxicity education with graded explanations, frequent health care team touchpoints especially during the challenging first 90 days, and addressing the unique adherence challenges in early-stage patients who are asymptomatic compared to metastatic patients.

Steven Pipe, MD, highlights the growing importance of pharmacists in hemophilia care as new therapies expand treatment complexity and require specialized expertise.

Canomiks enhances consumer trust in the supplement industry through WhatToTrust, a platform evaluating product safety, efficacy, and scientific validation.

This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.

Ron Lanton explains that increased pharmaceutical tariffs could drive up costs, reduce margins, and strain pharmacy supply chains, with few mitigation options available.

Pharmacists emphasize the importance of RSV awareness, testing, and vaccination for older adults and high-risk infants to enhance community health.

An expert discusses how enhanced EHR systems can boost vaccination rates by providing clinical alerts, integrating immunization histories, and enabling automated patient follow-ups—helping pharmacists identify opportunities, reduce missed doses, and improve overall vaccine delivery in retail settings.

An expert discusses innovative strategies to boost vaccine administration efficiency and accessibility—including prefilled syringes with attached needles, ergonomic and labeling improvements, needle-free options, and shelf-stable auto-injectors—all aimed at enhancing provider workflow and patient experience, especially in high-volume or underserved settings.

Pharmacists’ medication expertise strengthens clinical care and supports a more collaborative, team-based approach to patient health.

Ron Lanton advises pharmacies to maintain compliance, explore contingency options, and stay engaged with policymakers during the government shutdown.